2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUV
2005
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy
Roberts KB, Manus MP, Hicks RJ, Rischin D, Wirth A, Wright GM, Ball DL. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005, 47: 49-57. PMID: 15603854, DOI: 10.1016/j.lungcan.2004.06.014.Peer-Reviewed Original ResearchConceptsRadical radiotherapyExtensive diseaseNon-small cell lung cancerFluorodeoxyglucose positron emission tomographyRadical RTGood performance statusEvidence of diseaseAppropriateness of managementCell lung cancerEarly tumor progressionConcurrent chemotherapyIntrathoracic recurrenceThoracic recurrenceImpact of PETLimited diseaseProspective databaseTreatment intentPerformance statusRT doseSupportive careFurther patientsInflammatory changesUnexplained painClinical outcomesResidual tumor
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds